<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<!-- saved from url=(0052)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/ -->
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="brjclinpharm"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC2686069/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="./PMC2686069_files/jig.min.css"><script type="text/javascript" src="./PMC2686069_files/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="British Journal of Clinical Pharmacology"><meta name="citation_title" content="The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers"><meta name="citation_authors" content="Gennyne Walker, Arun Mandagere, Christopher Dufton, Jürgen Venitz"><meta name="citation_date" content="May 2009"><meta name="citation_issue" content="5"><meta name="citation_volume" content="67"><meta name="citation_firstpage" content="527"><meta name="citation_doi" content="10.1111/j.1365-2125.2009.03384.x"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC2686069/?report=abstract"><meta name="citation_pmid" content="19552747"><meta name="DC.Title" content="The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="Wiley-Blackwell"><meta name="DC.Contributor" content="Gennyne Walker"><meta name="DC.Contributor" content="Arun Mandagere"><meta name="DC.Contributor" content="Christopher Dufton"><meta name="DC.Contributor" content="Jürgen Venitz"><meta name="DC.Date" content="2009 May"><meta name="DC.Identifier" content="10.1111/j.1365-2125.2009.03384.x"><meta name="DC.Language" content="en"><meta property="og:title" content="The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers"><meta property="og:type" content="article"><meta property="og:description" content="Ambrisentan is an oral, propanoic acid-based endothelin receptor antagonist often co-administered with warfarin to patients with pulmonary arterial hypertension. The aim of this study was to evaluate the potential for ambrisentan to affect warfarin pharmacokinetics ..."><meta property="og:url" content="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><link rel="stylesheet" href="./PMC2686069_files/pmc.min.css" type="text/css"><link rel="stylesheet" href="./PMC2686069_files/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="./PMC2686069_files/common.min.js">//</script><script type="text/javascript" src="./PMC2686069_files/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:&#39;/pmc/utils/ctxp/&#39;"><script type="text/javascript" src="./PMC2686069_files/jquery.citationexporter.js">//</script><link rel="stylesheet" href="./PMC2686069_files/citationexporter.css" type="text/css"><script type="text/javascript" src="./PMC2686069_files/MathJax.js"></script><script type="text/javascript" src="./PMC2686069_files/large-obj-scrollbars.min.js"></script><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-brjclinpharm.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><link rel="alternate" type="application/epub+zip" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/epub/"><link rel="alternate" type="application/pdf" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/pdf/bcp0067-0527.pdf">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="http://www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="F4FB0C9376C27161000000000082EC20"><link type="text/css" rel="stylesheet" href="./PMC2686069_files/3855312.css"><link type="text/css" rel="stylesheet" href="./PMC2686069_files/3929378.css" media="print"><style type="text/css" media="print">.print-log { position:absolute;left:-10000px;top:auto;width:1px;height:1px;overflow:hidden; }.print-log li { list-style-image: url('http://www.ncbi.nlm.nih.gov/stat?jsevent=print&ncbi_app=pmc&ncbi_db=pmc&ncbi_pcid=%2Farticles%2FPMC2686069%2F&ncbi_pdid=article&ncbi_phid=F4FB0C9376C27161000000000082EC20'); }</style><style type="text/css">.print-log { position:absolute;left:-10000px;top:auto;width:1px;height:1px;overflow:hidden; }</style><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1em; bottom: 1.5em; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 5px 0px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; -khtml-border-radius: 5px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 1px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: .7em}
.MathJax_MenuRadioCheck.RTL {right: .7em; left: auto}
.MathJax_MenuLabel {padding: 1px 2em 3px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #DDDDDD; margin: 4px 3px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: #606872; color: white}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style></head>
    <body class="article" id="ui-jig-5"><div id="MathJax_Message" style="display: none;"></div>
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	&lt;p class="nojs"&gt;
	&lt;strong&gt;Warning:&lt;/strong&gt;
	The NCBI web site requires JavaScript to function. 
	&lt;a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank"&gt;more...&lt;/a&gt;
	&lt;/p&gt;
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="http://www.ncbi.nlm.nih.gov/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="./PMC2686069_files/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="http://www.ncbi.nlm.nih.gov/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a><ul id="resources-submenu" class="ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/all/" tabindex="-1" role="menuitem">All Resources</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#chemicals-bioassays" tabindex="-1" role="menuitem" class="expandRight">Chemicals &amp; Bioassays</a><ul class="actual-resources-submenu chemicals-bioassays ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/biosystems/" title=" Database that groups biomedical literature, small molecules, and sequence data in terms of biological relationships. " tabindex="-1" role="menuitem">BioSystems</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pcassay" title=" Contributed bioactivity data for PubChem Substances " tabindex="-1" role="menuitem">PubChem BioAssay</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pccompound" title=" Unique, standardized chemical structures " tabindex="-1" role="menuitem">PubChem Compound</a></li><li role="presentation"><a href="https://pubchem.ncbi.nlm.nih.gov/search/search.cgi" title=" Searches PubChem Compound by chemical structure " tabindex="-1" role="menuitem">PubChem Structure Search</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pcsubstance" title=" Provides information on the biological activities of small molecules. " tabindex="-1" role="menuitem">PubChem Substance</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/chemicals-bioassays/" tabindex="-1" role="menuitem">All Chemicals &amp; Bioassays Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#dna-rna" tabindex="-1" role="menuitem" class="expandRight">DNA &amp; RNA</a><ul class="actual-resources-submenu dna-rna ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi" title=" Tool for finding local regions of sequence similarity " tabindex="-1" role="menuitem">BLAST (Basic Local Alignment Search Tool)</a></li><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&amp;PAGE_TYPE=BlastDocs&amp;DOC_TYPE=Download" title=" BLAST programs for a local computer " tabindex="-1" role="menuitem">BLAST (Stand-alone)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK25501/" title=" URL application programming interface for searching, linking and downloading data within NCBI&#39;s Entrez system " tabindex="-1" role="menuitem">E-Utilities</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genbank/" title=" DNA and RNA sequences submitted to NCBI " tabindex="-1" role="menuitem">GenBank</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/WebSub/?tool=genbank" title=" Web tool for simple submissions of nucleotide sequences " tabindex="-1" role="menuitem">GenBank: BankIt</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/projects/Sequin/" title=" Software tool for complex submissions of nucleotide sequences " tabindex="-1" role="menuitem">GenBank: Sequin</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genbank/tbl2asn2/" title=" Command-line program for submitting sequence data " tabindex="-1" role="menuitem">GenBank: tbl2asn</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/gbench/" title=" Stand-alone application for analyzing sequence data " tabindex="-1" role="menuitem">Genome Workbench</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genomes/FLU/" title=" Data from the NIAID Influenza Genome Sequencing Project " tabindex="-1" role="menuitem">Influenza Virus</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/nuccore" title=" Nucleotide sequence data in GenBank and RefSeq " tabindex="-1" role="menuitem">Nucleotide Database</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/popset" title=" Sets of nucleotide sequences representing a population " tabindex="-1" role="menuitem">PopSet</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/primer-blast/" title=" Designs PCR primers and analyzes them for target specificity using BLAST. " tabindex="-1" role="menuitem">Primer-BLAST</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/static/prosplign/prosplign.html" title=" Tool for aligning proteins to genomic DNA " tabindex="-1" role="menuitem">ProSplign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/refseq/" title=" Curated nucleotide and protein sequences produced by NCBI " tabindex="-1" role="menuitem">Reference Sequence (RefSeq)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/refseq/rsg/" title=" RefSeqGene reference standards for genomic sequences of well-characterized genes " tabindex="-1" role="menuitem">RefSeqGene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?" title=" Database of sequences reads from next generation sequencing technologies " tabindex="-1" role="menuitem">Sequence Read Archive (SRA)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/splign/" title=" Tool for aligning transcripts to genomic DNA " tabindex="-1" role="menuitem">Splign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Traces/trace.cgi" title=" DNA chromatograms, base calls, and quality estimates for single-pass reads. " tabindex="-1" role="menuitem">Trace Archive</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/unigene" title=" Gene-centered clusters of transcripts and ESTs " tabindex="-1" role="menuitem">UniGene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/dna-rna/" tabindex="-1" role="menuitem">All DNA &amp; RNA Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#data-software" tabindex="-1" role="menuitem" class="expandRight">Data &amp; Software</a><ul class="actual-resources-submenu data-software ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi" title=" Tool for finding local regions of sequence similarity " tabindex="-1" role="menuitem">BLAST (Basic Local Alignment Search Tool)</a></li><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&amp;PAGE_TYPE=BlastDocs&amp;DOC_TYPE=Download" title=" BLAST programs for a local computer " tabindex="-1" role="menuitem">BLAST (Stand-alone)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/CN3D/cn3d.shtml" title=" Program for viewing 3D structures and alignments " tabindex="-1" role="menuitem">Cn3D</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi" title=" Locates conserved domains within a protein sequence " tabindex="-1" role="menuitem">Conserved Domain Search Service (CD Search)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK25501/" title=" URL application programming interface for searching, linking and downloading data within NCBI&#39;s Entrez system " tabindex="-1" role="menuitem">E-Utilities</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/WebSub/?tool=genbank" title=" Web tool for simple submissions of nucleotide sequences " tabindex="-1" role="menuitem">GenBank: BankIt</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/projects/Sequin/" title=" Software tool for complex submissions of nucleotide sequences " tabindex="-1" role="menuitem">GenBank: Sequin</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genbank/tbl2asn2/" title=" Command-line program for submitting sequence data " tabindex="-1" role="menuitem">GenBank: tbl2asn</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/protmap.cgi" title=" Maps proteins from a COG/VOG back to its genome " tabindex="-1" role="menuitem">Genome ProtMap</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/gbench/" title=" Stand-alone application for analyzing sequence data " tabindex="-1" role="menuitem">Genome Workbench</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/primer-blast/" title=" Designs PCR primers and analyzes them for target specificity using BLAST. " tabindex="-1" role="menuitem">Primer-BLAST</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/static/prosplign/prosplign.html" title=" Tool for aligning proteins to genomic DNA " tabindex="-1" role="menuitem">ProSplign</a></li><li role="presentation"><a href="https://pubchem.ncbi.nlm.nih.gov/search/search.cgi" title=" Searches PubChem Compound by chemical structure " tabindex="-1" role="menuitem">PubChem Structure Search</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/projects/SNP/" title=" The SNP database tools page provides links to the general submission guidelines and to the submission handle request. " tabindex="-1" role="menuitem">SNP Submission Tool</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/splign/" title=" Tool for aligning transcripts to genomic DNA " tabindex="-1" role="menuitem">Splign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/VAST/vast.html" title=" Tool that generates 3D structural alignments " tabindex="-1" role="menuitem">Vector Alignment Search Tool (VAST)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/data-software/" tabindex="-1" role="menuitem">All Data &amp; Software Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#domains-structures" tabindex="-1" role="menuitem" class="expandRight">Domains &amp; Structures</a><ul class="actual-resources-submenu domains-structures ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/biosystems/" title=" Database that groups biomedical literature, small molecules, and sequence data in terms of biological relationships. " tabindex="-1" role="menuitem">BioSystems</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/CN3D/cn3d.shtml" title=" Program for viewing 3D structures and alignments " tabindex="-1" role="menuitem">Cn3D</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/cdd" title=" Database of conserved protein domains represented by multiple sequence alignments " tabindex="-1" role="menuitem">Conserved Domain Database (CDD)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi" title=" Locates conserved domains within a protein sequence " tabindex="-1" role="menuitem">Conserved Domain Search Service (CD Search)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/structure/" title=" Database of 3D macromolecular structures derived from PDB " tabindex="-1" role="menuitem">Structure (Molecular Modeling Database)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/VAST/vast.html" title=" Tool that generates 3D structural alignments " tabindex="-1" role="menuitem">Vector Alignment Search Tool (VAST)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/domains-structures/" tabindex="-1" role="menuitem">All Domains &amp; Structures Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#genes-expression" tabindex="-1" role="menuitem" class="expandRight">Genes &amp; Expression</a><ul class="actual-resources-submenu genes-expression ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/biosystems/" title=" Database that groups biomedical literature, small molecules, and sequence data in terms of biological relationships. " tabindex="-1" role="menuitem">BioSystems</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/gap" title=" Genotype/Phenotype association studies " tabindex="-1" role="menuitem">Database of Genotypes and Phenotypes (dbGaP)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK25501/" title=" URL application programming interface for searching, linking and downloading data within NCBI&#39;s Entrez system " tabindex="-1" role="menuitem">E-Utilities</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/gene" title=" Database of gene loci and associated transcripts and proteins " tabindex="-1" role="menuitem">Gene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/geo/" title=" Gene Expression Omnibus (GEO) Database " tabindex="-1" role="menuitem">Gene Expression Omnibus (GEO) Database </a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/gds" title=" Curated collections of gene expression data sets " tabindex="-1" role="menuitem">Gene Expression Omnibus (GEO) Datasets</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/geoprofiles/" title=" Database of gene expression Profiles for individual sequences " tabindex="-1" role="menuitem">Gene Expression Omnibus (GEO) Profiles</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/gbench/" title=" Stand-alone application for analyzing sequence data " tabindex="-1" role="menuitem">Genome Workbench</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/homologene" title=" Sets of homologous eukaryotic genes " tabindex="-1" role="menuitem">HomoloGene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/mapview/" title=" Tool for searching, viewing and downloading genomic maps and related data " tabindex="-1" role="menuitem">Map Viewer</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/omim" title=" Database of human genes and genetic disorders " tabindex="-1" role="menuitem">Online Mendelian Inheritance in Man (OMIM)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/refseq/rsg/" title=" RefSeqGene reference standards for genomic sequences of well-characterized genes " tabindex="-1" role="menuitem">RefSeqGene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/unigene" title=" Gene-centered clusters of transcripts and ESTs " tabindex="-1" role="menuitem">UniGene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/genes-expression/" tabindex="-1" role="menuitem">All Genes &amp; Expression Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#genetics-medicine" tabindex="-1" role="menuitem" class="expandRight">Genetics &amp; Medicine</a><ul class="actual-resources-submenu genetics-medicine ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books" title=" Online biomedical books " tabindex="-1" role="menuitem">Bookshelf</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/gap" title=" Genotype/Phenotype association studies " tabindex="-1" role="menuitem">Database of Genotypes and Phenotypes (dbGaP)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/gtr/" title=" Detailed information about genetic tests and labs " tabindex="-1" role="menuitem">Genetic Testing Registry</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genomes/FLU/" title=" Data from the NIAID Influenza Genome Sequencing Project " tabindex="-1" role="menuitem">Influenza Virus</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/mapview/" title=" Tool for searching, viewing and downloading genomic maps and related data " tabindex="-1" role="menuitem">Map Viewer</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/omim" title=" Database of human genes and genetic disorders " tabindex="-1" role="menuitem">Online Mendelian Inheritance in Man (OMIM)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pubmed" title=" Biomedical literature abstracts " tabindex="-1" role="menuitem">PubMed</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/" title=" Free, full-text articles " tabindex="-1" role="menuitem">PubMed Central (PMC)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pubmed/clinical" title=" Directory of PubMed queries about clinical topics " tabindex="-1" role="menuitem">PubMed Clinical Queries</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/refseq/rsg/" title=" RefSeqGene reference standards for genomic sequences of well-characterized genes " tabindex="-1" role="menuitem">RefSeqGene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/genetics-medicine/" tabindex="-1" role="menuitem">All Genetics &amp; Medicine Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#genomes-maps" tabindex="-1" role="menuitem" class="expandRight">Genomes &amp; Maps</a><ul class="actual-resources-submenu genomes-maps ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/dbvar" title=" A database of genomic structural variation " tabindex="-1" role="menuitem">Database of Genomic Structural Variation (dbVar)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genbank/tbl2asn2/" title=" Command-line program for submitting sequence data " tabindex="-1" role="menuitem">GenBank: tbl2asn</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sites/genome" title=" Curated genomic DNA sequences " tabindex="-1" role="menuitem">Genome</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/bioproject/" title=" Central status pages for genome sequencing projects " tabindex="-1" role="menuitem">Genome Project</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/protmap.cgi" title=" Maps proteins from a COG/VOG back to its genome " tabindex="-1" role="menuitem">Genome ProtMap</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/gbench/" title=" Stand-alone application for analyzing sequence data " tabindex="-1" role="menuitem">Genome Workbench</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genomes/FLU/" title=" Data from the NIAID Influenza Genome Sequencing Project " tabindex="-1" role="menuitem">Influenza Virus</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/mapview/" title=" Tool for searching, viewing and downloading genomic maps and related data " tabindex="-1" role="menuitem">Map Viewer</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/nuccore" title=" Nucleotide sequence data in GenBank and RefSeq " tabindex="-1" role="menuitem">Nucleotide Database</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/popset" title=" Sets of nucleotide sequences representing a population " tabindex="-1" role="menuitem">PopSet</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/static/prosplign/prosplign.html" title=" Tool for aligning proteins to genomic DNA " tabindex="-1" role="menuitem">ProSplign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?" title=" Database of sequences reads from next generation sequencing technologies " tabindex="-1" role="menuitem">Sequence Read Archive (SRA)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/splign/" title=" Tool for aligning transcripts to genomic DNA " tabindex="-1" role="menuitem">Splign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Traces/trace.cgi" title=" DNA chromatograms, base calls, and quality estimates for single-pass reads. " tabindex="-1" role="menuitem">Trace Archive</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/genomes-maps/" tabindex="-1" role="menuitem">All Genomes &amp; Maps Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#homology" tabindex="-1" role="menuitem" class="expandRight">Homology</a><ul class="actual-resources-submenu homology ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi" title=" Tool for finding local regions of sequence similarity " tabindex="-1" role="menuitem">BLAST (Basic Local Alignment Search Tool)</a></li><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&amp;PAGE_TYPE=BlastDocs&amp;DOC_TYPE=Download" title=" BLAST programs for a local computer " tabindex="-1" role="menuitem">BLAST (Stand-alone)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/blink.cgi?mode=query" title=" Pre-computed reports showing proteins with similar sequences " tabindex="-1" role="menuitem">BLAST Link (BLink)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/cdd" title=" Database of conserved protein domains represented by multiple sequence alignments " tabindex="-1" role="menuitem">Conserved Domain Database (CDD)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi" title=" Locates conserved domains within a protein sequence " tabindex="-1" role="menuitem">Conserved Domain Search Service (CD Search)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/protmap.cgi" title=" Maps proteins from a COG/VOG back to its genome " tabindex="-1" role="menuitem">Genome ProtMap</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/homologene" title=" Sets of homologous eukaryotic genes " tabindex="-1" role="menuitem">HomoloGene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/proteinclusters" title=" Clusters of related proteins from prokaryotes and organelles " tabindex="-1" role="menuitem">Protein Clusters</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/homology/" tabindex="-1" role="menuitem">All Homology Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#literature" tabindex="-1" role="menuitem" class="expandRight">Literature</a><ul class="actual-resources-submenu literature ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books" title=" Online biomedical books " tabindex="-1" role="menuitem">Bookshelf</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK25501/" title=" URL application programming interface for searching, linking and downloading data within NCBI&#39;s Entrez system " tabindex="-1" role="menuitem">E-Utilities</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/nlmcatalog/journals" title=" Information on journals cited by NCBI records " tabindex="-1" role="menuitem">Journals in NCBI Databases</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/mesh" title=" Controlled vocabulary for MEDLINE " tabindex="-1" role="menuitem">MeSH Database</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK143764/" title=" Introductory articles about NCBI resources " tabindex="-1" role="menuitem">NCBI Handbook</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK3831/" title=" Online, searchable help documentation " tabindex="-1" role="menuitem">NCBI Help Manual</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK1969/" title=" NCBI&#39;s monthly newsletter " tabindex="-1" role="menuitem">NCBI News</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pubmed" title=" Biomedical literature abstracts " tabindex="-1" role="menuitem">PubMed</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/" title=" Free, full-text articles " tabindex="-1" role="menuitem">PubMed Central (PMC)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pubmed/clinical" title=" Directory of PubMed queries about clinical topics " tabindex="-1" role="menuitem">PubMed Clinical Queries</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pubmedhealth/" title=" Reviews of clinical effectiveness research " tabindex="-1" role="menuitem">PubMed Health</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/literature/" tabindex="-1" role="menuitem">All Literature Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#proteins" tabindex="-1" role="menuitem" class="expandRight">Proteins</a><ul class="actual-resources-submenu proteins ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/biosystems/" title=" Database that groups biomedical literature, small molecules, and sequence data in terms of biological relationships. " tabindex="-1" role="menuitem">BioSystems</a></li><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi" title=" Tool for finding local regions of sequence similarity " tabindex="-1" role="menuitem">BLAST (Basic Local Alignment Search Tool)</a></li><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&amp;PAGE_TYPE=BlastDocs&amp;DOC_TYPE=Download" title=" BLAST programs for a local computer " tabindex="-1" role="menuitem">BLAST (Stand-alone)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/blink.cgi?mode=query" title=" Pre-computed reports showing proteins with similar sequences " tabindex="-1" role="menuitem">BLAST Link (BLink)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/cdd" title=" Database of conserved protein domains represented by multiple sequence alignments " tabindex="-1" role="menuitem">Conserved Domain Database (CDD)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi" title=" Locates conserved domains within a protein sequence " tabindex="-1" role="menuitem">Conserved Domain Search Service (CD Search)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK25501/" title=" URL application programming interface for searching, linking and downloading data within NCBI&#39;s Entrez system " tabindex="-1" role="menuitem">E-Utilities</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/static/prosplign/prosplign.html" title=" Tool for aligning proteins to genomic DNA " tabindex="-1" role="menuitem">ProSplign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/proteinclusters" title=" Clusters of related proteins from prokaryotes and organelles " tabindex="-1" role="menuitem">Protein Clusters</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/protein" title=" Protein sequence data " tabindex="-1" role="menuitem">Protein Database</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/refseq/" title=" Curated nucleotide and protein sequences produced by NCBI " tabindex="-1" role="menuitem">Reference Sequence (RefSeq)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/proteins/" tabindex="-1" role="menuitem">All Proteins Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#sequence-analysis" tabindex="-1" role="menuitem" class="expandRight">Sequence Analysis</a><ul class="actual-resources-submenu sequence-analysis ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi" title=" Tool for finding local regions of sequence similarity " tabindex="-1" role="menuitem">BLAST (Basic Local Alignment Search Tool)</a></li><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&amp;PAGE_TYPE=BlastDocs&amp;DOC_TYPE=Download" title=" BLAST programs for a local computer " tabindex="-1" role="menuitem">BLAST (Stand-alone)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/blink.cgi?mode=query" title=" Pre-computed reports showing proteins with similar sequences " tabindex="-1" role="menuitem">BLAST Link (BLink)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi" title=" Locates conserved domains within a protein sequence " tabindex="-1" role="menuitem">Conserved Domain Search Service (CD Search)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/protmap.cgi" title=" Maps proteins from a COG/VOG back to its genome " tabindex="-1" role="menuitem">Genome ProtMap</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/gbench/" title=" Stand-alone application for analyzing sequence data " tabindex="-1" role="menuitem">Genome Workbench</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genomes/FLU/" title=" Data from the NIAID Influenza Genome Sequencing Project " tabindex="-1" role="menuitem">Influenza Virus</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/primer-blast/" title=" Designs PCR primers and analyzes them for target specificity using BLAST. " tabindex="-1" role="menuitem">Primer-BLAST</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/static/prosplign/prosplign.html" title=" Tool for aligning proteins to genomic DNA " tabindex="-1" role="menuitem">ProSplign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/splign/" title=" Tool for aligning transcripts to genomic DNA " tabindex="-1" role="menuitem">Splign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/sequence-analysis/" tabindex="-1" role="menuitem">All Sequence Analysis Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#taxonomy" tabindex="-1" role="menuitem" class="expandRight">Taxonomy</a><ul class="actual-resources-submenu taxonomy ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/taxonomy" title=" The NCBI taxonomy tree in Entrez " tabindex="-1" role="menuitem">Taxonomy</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Root" title=" Displays and links Entrez data to each taxonomic node " tabindex="-1" role="menuitem">Taxonomy Browser</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Taxonomy/CommonTree/wwwcmt.cgi" title=" Creates custom taxonomic trees " tabindex="-1" role="menuitem">Taxonomy Common Tree</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/taxonomy/" tabindex="-1" role="menuitem">All Taxonomy Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#training-tutorials" tabindex="-1" role="menuitem" class="expandRight">Training &amp; Tutorials</a><ul class="actual-resources-submenu training-tutorials ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/education/" title=" Central page providing links to tutorials and training materials " tabindex="-1" role="menuitem">NCBI Education Page</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK143764/" title=" Introductory articles about NCBI resources " tabindex="-1" role="menuitem">NCBI Handbook</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK3831/" title=" Online, searchable help documentation " tabindex="-1" role="menuitem">NCBI Help Manual</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK1969/" title=" NCBI&#39;s monthly newsletter " tabindex="-1" role="menuitem">NCBI News</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/training-tutorials/" tabindex="-1" role="menuitem">All Training &amp; Tutorials Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#variation" tabindex="-1" role="menuitem" class="expandRight">Variation</a><ul class="actual-resources-submenu variation ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/dbvar" title=" A database of genomic structural variation " tabindex="-1" role="menuitem">Database of Genomic Structural Variation (dbVar)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/gap" title=" Genotype/Phenotype association studies " tabindex="-1" role="menuitem">Database of Genotypes and Phenotypes (dbGaP)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/snp" title=" Database of nucleotide sequence polymorphisms " tabindex="-1" role="menuitem">Database of Single Nucleotide Polymorphisms (dbSNP)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/projects/SNP/" title=" The SNP database tools page provides links to the general submission guidelines and to the submission handle request. " tabindex="-1" role="menuitem">SNP Submission Tool</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/variation/" tabindex="-1" role="menuitem">All Variation Resources...</a></li></ul></li></ul></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="http://www.ncbi.nlm.nih.gov/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a><ul id="howto-submenu" class="ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/all/#howtos" tabindex="-1" role="menuitem">All How To</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/chemicals-bioassays/#howtos" tabindex="-1" role="menuitem">Chemicals &amp; Bioassays</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/dna-rna/#howtos" tabindex="-1" role="menuitem">DNA &amp; RNA</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/data-software/#howtos" tabindex="-1" role="menuitem">Data &amp; Software</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/domains-structures/#howtos" tabindex="-1" role="menuitem">Domains &amp; Structures</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/genes-expression/#howtos" tabindex="-1" role="menuitem">Genes &amp; Expression</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/genetics-medicine/#howtos" tabindex="-1" role="menuitem">Genetics &amp; Medicine</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/genomes-maps/#howtos" tabindex="-1" role="menuitem">Genomes &amp; Maps</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/homology/#howtos" tabindex="-1" role="menuitem">Homology</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/literature/#howtos" tabindex="-1" role="menuitem">Literature</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/proteins/#howtos" tabindex="-1" role="menuitem">Proteins</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/sequence-analysis/#howtos" tabindex="-1" role="menuitem">Sequence Analysis</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/taxonomy/#howtos" tabindex="-1" role="menuitem">Taxonomy</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/training-tutorials/#howtos" tabindex="-1" role="menuitem">Training &amp; Tutorials</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/variation/#howtos" tabindex="-1" role="menuitem">Variation</a></li></ul></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="http://www.ncbi.nlm.nih.gov/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="http://www.ncbi.nlm.nih.gov/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="http://www.ncbi.nlm.nih.gov/account/?back_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2686069%2F" id="sign_in">Sign in to NCBI</a><a href="http://www.ncbi.nlm.nih.gov/account/signout/?back_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2686069%2F" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo">
  <h1 class="img_logo"><a href="http://www.ncbi.nlm.nih.gov/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="http://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="http://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="http://www.ncbi.nlm.nih.gov/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="pubmed" class="last">PubMed</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="clone">Clone</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="nucest">EST</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="nucgss">GSS</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="pubmedhealth">PubMed Health</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbook">ToolKitBook</option><option value="toolkitbookgh">ToolKitBookgh</option><option value="unigene">UniGene</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="ui-ncbiclearbutton-wrap box-shadow"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" config="dictionary:&#39;pmc-search-autocomplete&#39;,disableUrl:&#39;NcbiSearchBarAutoComplCtrl&#39;" autocomplete="off" data-sbconfig="ds:&#39;no&#39;,pjs:&#39;no&#39;,afs:&#39;yes&#39;" aria-haspopup="true" aria-autocomplete="list" role="textbox"><a class="reset" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#" style="visibility: hidden;"><img src="./PMC2686069_files/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/limits/">Limits</a>
                    </li><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="http://www.ncbi.nlm.nih.gov/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="http://www.ncbi.nlm.nih.gov/pmc/journals/" class="navlink">Journal List</a></li><li class="archive-page"><a class="navlink" href="http://www.ncbi.nlm.nih.gov/pmc/journals/279/">Br J Clin Pharmacol</a></li><li class="issue-page"><a class="navlink" href="http://www.ncbi.nlm.nih.gov/pmc/issues/179035/">v.67(5); 2009 May</a></li><li class="accid">PMC2686069</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="./PMC2686069_files/logo-brjclinpharm.gif" alt="Logo of brjclinpharm" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher&#39;s site" title="Link to Publisher&#39;s site" shape="default" coords="0,0,499,74" href="http://www.blackwellpublishing.com/journal.asp?ref=0306-5251" target="pmc_ext" ref="reftype=publisher&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [&#39;h2&#39;], headingExclude: &#39;:hidden&#39;" id="ui-jig-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="small"><div class="inline_block eight_col va_top"><div><div><span class="cit">Br J Clin Pharmacol. 2009 May; 67(5): 527–534. </span></div><div>  <span class="doi">doi:&nbsp; <a href="http://dx.doi.org/10.1111%2Fj.1365-2125.2009.03384.x" target="pmc_ext" ref="reftype=other&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">10.1111/j.1365-2125.2009.03384.x</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC2686069</span></div></div></div></div></div><h1 class="content-title">The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Walker%20G%5Bauth%5D">Gennyne Walker</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Mandagere%20A%5Bauth%5D">Arun Mandagere</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Dufton%20C%5Bauth%5D">Christopher Dufton</a>, and  <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Venitz%20J%5Bauth%5D">Jürgen Venitz</a><sup>1</sup></div></div><div class="fm-panel small half_rhythm"><div class="fm-authors-info fm-panel hide half_rhythm" id="id676465_ai" style="display:none"><div class="fm-affl" lang="en">Gilead Sciences Inc., Westminster, CO, USA</div><div class="fm-affl" lang="en"><sup>1</sup>Virginia Commonwealth University, Richmond, VA, USA</div><div id="cor1">Correspondence Gennyne Walker, PhD, Gilead Sciences Inc., 3333 Walnut Street, Boulder, CO 80301, USA. Tel: + 1 720 887 8650 Fax: + 1 720 887 8680 E-mail: <a href="mailto:dev@null" data-email="moc.daelig@reklaw.enynneg" class="oemail">moc.daelig@reklaw.enynneg</a></div></div><div class="togglers"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#" class="pmctoggle" rid="id676465_ai">Author information <span>►</span></a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#" class="pmctoggle" rid="id676465_an">Article notes <span>►</span></a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#" class="pmctoggle" rid="id676465_cpl">Copyright and License information <span>►</span></a></div><div class="fm-article-notes fm-panel hide half_rhythm" id="id676465_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2008 May 17; Accepted 2009 Feb 1.</div></div><div class="fm-cpl-info fm-panel hide half_rhythm" id="id676465_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="http://www.ncbi.nlm.nih.gov/pmc/about/copyright.html">Copyright</a> Journal compilation © 2009 The British Pharmacological Society</div></div></div><div class="links-box fm-panel whole_rhythm"><div class="small"><div>This article has been <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="__abstractid588690" lang="en" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-7"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true" id="ui-jig-8">Go to:</a></span></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__abstractid588690title">Abstract</h2><!--article-meta--><div><div id="__sec1" class="sec sec-first"><h3>AIMS</h3><p id="__p1" class="p p-first-last">Ambrisentan is an oral, propanoic acid-based endothelin receptor antagonist often co-administered with warfarin to patients with pulmonary arterial hypertension. The aim of this study was to evaluate the potential for ambrisentan to affect warfarin pharmacokinetics and pharmacodynamics.</p></div><div id="__sec2" class="sec"><h3>METHODS</h3><p id="__p2" class="p p-first-last">In this open-label cross-over study, 22 healthy subjects received a single dose of racemic warfarin 25 mg alone and after 8 days of ambrisentan 10 mg once daily. Assessments included exposure (AUC<sub>0–last</sub>) and maximum plasma concentration (<em>C</em><sub>max</sub>) for R-and S-warfarin, and International Normalized Ratio maximum observed value (INR<sub>max</sub>) and area under the curve (INR<sub>AUC(0–last)</sub>). The effects of warfarin on ambrisentan steady-state pharmacokinetics and the safety of ambrisentan/warfarin co-administration were assessed. Data are presented as geometric mean ratios.</p></div><div id="__sec3" class="sec"><h3>RESULTS</h3><p id="__p3" class="p p-first-last">Ambrisentan had no significant effects on the AUC<sub>0–last</sub> of R-warfarin [104.7; 90% confidence interval (CI) 101.7, 107.7) or S-warfarin (101.6; 90% CI 98.4, 105.0). Similarly, ambrisentan had no significant effects on the <em>C</em><sub>max</sub> of R-warfarin (91.6; 90% CI 86.2, 97.4) or S-warfarin (89.9; 90% CI 84.8, 95.3). Consistent with these observations, little pharmacodynamic change was observed for INR<sub>max</sub> (85.3; 90% CI 82.4, 88.2) or INR<sub>AUC(0–last)</sub> (93.0; 90% CI 90.8, 95.3). In addition, co-administration of warfarin did not alter ambrisentan steady-state pharmacokinetics. Adverse events were infrequent, and there were no bleeding adverse events.</p></div><div id="__sec4" class="sec sec-last"><h3>CONCLUSIONS</h3><p id="__p4" class="p p-first-last">Multiple doses of ambrisentan had no clinically relevant effects on the pharmacokinetics and pharmacodynamics of a single dose of warfarin. Therefore, significant dose adjustments of either drug are unlikely to be required with co-administration.</p></div></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">ambrisentan, endothelin receptor antagonist, International Normalized Ratio, pharmacodynamics, pharmacokinetics, pulmonary arterial hypertension, R-warfarin, S-warfarin</span></div></div><div id="__bodyid924750" class="tsec sec headless whole_rhythm"><div class="boxed-text-box whole_rhythm hide-overflow"><div class="sec"><h3>WHAT IS ALRADY KNOWN ABOUT THIS SUBJECT</h3><ul class="unordered" style="list-style-type:disc"><!--
list-behavior=unordered
prefix-word=
mark-type=disc
--><li><div>Warfarin anticoagulation therapy is commonly administered to patients with pulmonary arterial hypertension (PAH) to reduce the risk of thrombosis and embolism.</div></li><li><div>Ambrisentan is an orally active, propanoic acid-based endothelin receptor antagonist that is likely to be co-administered with warfarin to PAH patients.</div></li><li><div>Concomitant therapies that induce or inhibit warfarin metabolism may alter the systemic exposure of warfarin and significantly alter clotting time, as measured by prothrombin time and International Normalized Ratio, thereby requiring substantial adjustments to warfarin dose.</div></li></ul></div></div><div class="boxed-text-box whole_rhythm hide-overflow"><div class="sec"><h3>WHAT THIS STUDY ADDS</h3><ul class="unordered" style="list-style-type:disc"><!--
list-behavior=unordered
prefix-word=
mark-type=disc
--><li><div>This study was undertaken in healthy subjects to identify any potential drug interactions between ambrisentan and warfarin.</div></li><li><div>Multiple doses of ambrisentan had no clinically relevant effects on the pharmacokinetics or pharmacodynamics of warfarin; conversely, a single dose of warfarin had no clinically relevant effects on the steady-state pharmacokinetics of ambrisentan.</div></li><li><div>Therefore, co-administration of ambrisentan with warfarin should not require adjustment of the therapeutically effective dosing regimen for either drug.</div></li></ul></div></div></div><div id="__sec7" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-9"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-10">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec7title">Introduction</h2><p id="__p11" class="p p-first">Pulmonary arterial hypertension (PAH) is a serious and life-threatening disease characterized by progressive vasoconstriction, vascular remodelling and <em>in situ</em> thrombosis [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b1" rid="b1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_171511356" role="button" aria-expanded="false" aria-haspopup="true">1</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b2" rid="b2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_171511342" role="button" aria-expanded="false" aria-haspopup="true">2</a>]. Disease progression is associated with significant increases in pulmonary vascular resistance and sustained elevations in pulmonary artery pressure, which ultimately lead to right ventricular failure and death [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b1" rid="b1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_171511352" role="button" aria-expanded="false" aria-haspopup="true">1</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b3" rid="b3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_171511340" role="button" aria-expanded="false" aria-haspopup="true">3</a>].</p><p id="__p12">Prothrombotic changes, including increased platelet activity, are characteristic of PAH [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b2" rid="b2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_171511343" role="button" aria-expanded="false" aria-haspopup="true">2</a>]; therefore, anticoagulants such as warfarin are commonly administered to prevent thrombus formation in this patient population [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b4" rid="b4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_171511346" role="button" aria-expanded="false" aria-haspopup="true">4</a>]. The pharmacodynamic response to warfarin includes increased prothrombin time (PT), which is often expressed as an International Normalized Ratio (INR) [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b5" rid="b5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_171511338" role="button" aria-expanded="false" aria-haspopup="true">5</a>]. Warfarin is administered as a racemic mixture of R(+) and S(–) enantiomers, and the S-enantiomer is approximately two-to fivefold more potent than the R-enantiomer with respect to coagulation activity [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b6" rid="b6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_171511353" role="button" aria-expanded="false" aria-haspopup="true">6</a>]. Both warfarin enantiomers are metabolized in the liver by cytochrome P450 (CYP) isoenzymes: R-warfarin is primarily metabolized by CYP1A2 and CYP3A4, whereas S-warfarin is primarily metabolized by CYP2C9 [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b7" rid="b7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_171511351" role="button" aria-expanded="false" aria-haspopup="true">7</a>]. Concomitant therapies that alter CYP enzyme activities may alter the pharmacokinetic exposure of warfarin and significantly affect clotting time as measured by INR. Decreased INR could potentially lead to a higher risk of thromboembolism, while increased INR could result in significant bleeding episodes.</p><p id="__p13" class="p p-last">Endothelin receptor antagonists (ERAs) have emerged as a promising class of therapeutic agents for PAH [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b4" rid="b4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_171511345" role="button" aria-expanded="false" aria-haspopup="true">4</a>]. Bosentan and sitaxsentan are sulphonamide-based ERAs that have proven effective in the treatment of PAH [[<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b8" rid="b8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_171511354" role="button" aria-expanded="false" aria-haspopup="true">8</a>], [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b9" rid="b9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_171511344" role="button" aria-expanded="false" aria-haspopup="true">9</a>]; however, both drugs have been shown to alter warfarin metabolism by affecting the activity of CYP3A4 and CYP2C9. Ambrisentan is a once-daily, orally active, propanoic acid-based, receptor subtype A (ET<sub>A</sub>) selective ERA that is approved for the treatment of PAH. Ambrisentan has been shown to improve exercise capacity, delay time to clinical worsening, reduce disease symptoms, and improve cardiopulmonary haemodynamics in patients with PAH [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b10" rid="b10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_171511348" role="button" aria-expanded="false" aria-haspopup="true">10</a>–<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b12" rid="b12" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">12</a>]. Unlike bosentan and sitaxsentan, ambrisentan does not induce or inhibit CYP2C9 or CYP3A4 and is therefore unlikely to have drug–drug interactions with warfarin and other CYP-metabolized drugs [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b11" rid="b11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_320580656" role="button" aria-expanded="false" aria-haspopup="true">11</a>]. This study was undertaken to evaluate the effects of multiple doses of ambrisentan on the pharmacokinetics and pharmacodynamics of a single racemic dose of warfarin, as well as to assess the effects of warfarin on the steady-state pharmacokinetics of ambrisentan. In addition, the safety and tolerability of ambrisentan and warfarin co-administration were evaluated.</p></div><div id="__sec8" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-11"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-12">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec8title">Methods</h2><div id="__sec9" class="sec sec-first"><h3>Subjects</h3><p id="__p14" class="p p-first">Men and women aged 18–55 years with a body mass index of 18.5–29.9, weight ≥50 kg, and in good health were eligible for this study. Determination of health was based on a comprehensive pre-study examination that included medical history, physical examination, electrocardiogram (ECG) and clinical laboratory tests. Subjects were required to be nontobacco users, and agreed to discontinue the intake of caffeine, alcohol, grapefruit products, liver, and leafy green vegetables. At screening, subjects were also required to have PT, INR and partial thromboplastin time values within normal limits, serum aspartate aminotransferase and alanine aminotransferase concentrations &lt;1x the upper limit of normal, and negative laboratory results for human immunodeficiency virus, hepatitis B and hepatitis C. Female subjects were required to be surgically sterile by hysterectomy and/or bilateral oophorectomy.</p><p id="__p15" class="p p-last">Subjects were excluded if they had current evidence or history of alcohol dependence, bleeding disorders, sensitivity to warfarin or ambrisentan, or significant allergies. Subjects were also excluded if they had donated or received blood products within 30 days prior to the first dose of study drug, or had received any medication, herbal remedies, food or alcohol that were known to interfere with CYP enzyme metabolism within 2 weeks prior to the first dose of study drug. All participants provided written informed consent. The study was reviewed and approved by Aspire Independent Review Board (San Diego, CA, USA).</p></div><div id="__sec10" class="sec"><h3>Study design/treatments</h3><p id="__p16" class="p p-first">This was a Phase 1, open-label, fixed-sequence, two-way, crossover, single-centre study to evaluate the potential for a pharmacokinetic and/or pharmacodynamic interaction of multiple doses of ambrisentan with a single dose of warfarin in healthy subjects (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/figure/fig01/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="fig01" rid-ob="ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure 1</span></a>). Following a screening period of 21 days, subjects were administered a single dose of racemic warfarin 25 mg (Bristol-Myers Squibb, Princeton, NJ, USA) on day 1. On days 5 to 16, subjects received a single daily dose of ambrisentan 10 mg (Gilead Sciences, Inc., formerly Myogen, Inc., Westminster, CO, USA). On day 13, subjects were administered a single 10-mg dose of ambrisentan together with a single 25-mg dose of warfarin. All study medications were administered under fasted conditions and under the supervision of clinical study site personnel. This study was performed in compliance with the principles of Good Clinical Practice and the Declaration of Helsinki.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="fig01" co-legend-rid="lgnd_fig01"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/figure/fig01/" target="figure" rid-figpopup="fig01" rid-ob="ob-fig01"><img src="./PMC2686069_files/bcp0067-0527-f1.gif" class="small-thumb" alt="Figure 1" title="Figure 1" src-large="/pmc/articles/PMC2686069/bin/bcp0067-0527-f1.jpg"></a><div class="icnblk_cntnt" id="lgnd_fig01"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/figure/fig01/" target="figure" rid-figpopup="fig01" rid-ob="ob-fig01">Figure 1</a></div><!--caption a4--><div><span>Study dosing regimen and blood sampling schedule. Single doses of racemic warfarin 25 mg were administered on days 1 and 13, and ambrisentan 10 mg was administered once daily from day 5 to day 16. OD, once daily; PK, pharmacokinetics; PD, pharmacodynamics;</span> <strong>...</strong></div></div></div></div><div id="__sec11" class="sec"><h3>Pharmacokinetics and pharmacodynamics</h3><p id="__p18" class="p p-first-last">Blood samples for the pharmacokinetic assessments of R-and S-warfarin were collected at the following times relative to the day 1 and day 13 warfarin doses: predose (≤30 min prior), and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72 and 96 h postdose. Blood samples for ambrisentan pharmacokinetic assessments were collected relative to the day 12 and day 13 ambrisentan doses: predose (≤30 min prior), and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18 and 24 h postdose. Steady-state ambrisentan concentrations were determined from samples collected at trough (predose) on days 10 to 13. Blood samples were immediately mixed by gentle inversion of the tube eight to 10 times and placed in an ice bath. Within 30 min of collection, samples were centrifuged at 4°C at a minimum of 1500 <em>g</em> for 15 min until cells and plasma were well separated. Samples were divided into two aliquots and frozen at –20°C until analysis. Plasma concentrations of R-and S-warfarin were determined by a validated liquid chromatography tandem mass spectrometry (LC/MS/MS) method, with a lower limit of quantification of 1.0 ng ml<sup>−1</sup>[<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b13" rid="b13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_171511350" role="button" aria-expanded="false" aria-haspopup="true">13</a>]. Plasma concentrations of ambrisentan were determined by a validated LC/MS/MS method with a lower limit of quantification of 5.0 ng ml<sup>−1</sup>. The precision of the ambrisentan assay was &lt;15% as indicated by the percent coefficient of variation and the accuracy of the assay was within 15% of the actual value for ambrisentan. Pharmacokinetic analyses were performed using WinNonlin™ Professional Network Edition, Version 4.0.1 (Pharsight Corp, Palo Alto, CA, USA). Estimated plasma pharmacokinetic parameters for ambrisentan and warfarin enantiomers included area under the concentration–time curve from time 0 to last measurement (AUC<sub>0–last</sub>), maximum plasma concentration (<em>C</em><sub>max</sub>) and time to <em>C</em><sub>max</sub> (<em>t</em><sub>max</sub>). Minimum plasma concentrations (<em>C</em><sub>min</sub>) were also determined for the steady-state pharmacokinetic analysis of ambrisentan. Prothrombin times, presented as INR, were characterized using area under the effect–time curve from time 0 to the last measurable concentration (INR<sub>AUC(0–last)</sub>), maximum observed value (INR<sub>max</sub>) and time to reach maximum observed value (INR<sub>tmax</sub>).</p></div><div id="__sec12" class="sec"><h3>Safety</h3><p id="__p19" class="p p-first-last">The safety and tolerability of ambrisentan and warfarin co-administration was assessed through adverse events (AEs), vital signs, clinical laboratory evaluations and 12-lead ECG. AEs were monitored continuously during the study. Clinical laboratory parameters (including blood chemistry, haematology and urinalysis) and 12-lead ECG were assessed during the prestudy and poststudy examinations.</p></div><div id="__sec13" class="sec sec-last"><h3>Statistical methods</h3><p id="__p20" class="p p-first">Participants who received at least one dose of study drug were included in the safety assessment (intent-to-treat population). All subjects with plasma concentration data were included in the pharmacokinetic full analysis population. All subjects who received all doses of study drug and had sufficient blood samples and assessments to determine INR<sub>AUC(0–last)</sub>, INR<sub>max</sub> and INR<sub>tmax</sub> were included in the pharmacodynamic evaluable population.</p><p id="__p21">Pharmacokinetic and pharmacodynamic parameters are presented as arithmetic means and standard deviations, except for <em>t</em><sub>max</sub> values, which are presented as medians with ranges. Values for INR<sub>AUC(0–last)</sub> were calculated using the trapezoidal rule.</p><p id="__p22">To assess the effect of concomitant ambrisentan dosing on warfarin pharmacokinetics and pharmacodynamics, individual within-subject pair-wise differences of day 13 (warfarin + ambrisentan) <em>vs</em>. day 1 (warfarin alone) were summarized for the natural logarithms of <em>C</em><sub>max</sub> and AUC<sub>0–last</sub> for R-and S-warfarin, and the natural logarithms of INR<sub>max</sub> and INR<sub>AUC(0–last)</sub>. The comparisons of day 13/day 1 INR<sub>max</sub> and INR<sub>AUC(0–last)</sub> estimates were prospectively defined as the primary assessments of an interaction. All pharmacokinetic and pharmacodynamic comparisons were reported as geometric mean ratios (GMRs) with two-sided confidence intervals (CI; 90% CI for pharmacokinetic comparisons and 95% CI for pharmacodynamic comparisons), and expressed as percentages. A conclusion of no interaction was made if the entire CI was within the standard no effect boundaries of 80–125%. The Wilcoxon signed rank test was evaluated for the differences in <em>t</em><sub>max</sub> between treatment days for INR and R-and S-warfarin concentrations.</p><p id="__p23">To assess the effect of concomitant warfarin dosing on ambrisentan pharmacokinetics, individual within-subject pair-wise differences of day 13 (warfarin + ambrisentan) <em>vs</em>. day 12 (ambrisentan alone) were summarized for the natural logarithms of ambrisentan <em>C</em><sub>min,ss</sub>,<em>C</em><sub>max,ss</sub> and AUC<sub>0–τ,ss</sub>. These comparisons were reported as GMRs with 90% CI and expressed as percentages, and a conclusion of no interaction was made if the entire CI was within the standard no effect boundaries of 80–125%. The Wilcoxon signed rank test was evaluated for the differences in <em>t</em><sub>max</sub> between treatment days for ambrisentan concentrations.</p><p id="__p24" class="p p-last">A total of 22 subjects were enrolled to ensure that 18 subjects completed the study. With 18 subjects, the study had a &gt;80% power to detect a 6% difference in INR between day 13 (warfarin +ambrisentan) and day 1 (warfarin alone), and a &gt;90% probability that the true 95% two-sided CI for the comparison of day 13 and day 1 INR<sub>AUC(0–last)</sub> values was within 80–125%. All statistical analyses were performed using the SAS® program (Cary, NC, USA).</p></div></div><div id="__sec14" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-13"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-14">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec14title">Results</h2><p id="__p25" class="p p-first">A total of 22 healthy male (<em>n</em> = 19, 86.4%) and female (<em>n</em> = 3, 13.6%) subjects with a mean age of 38.8 ± 10.3 years and mean weight of 79.1 ± 10.4 kg were enrolled. All 22 enrolled subjects completed the study according to the protocol and received two doses of racemic warfarin 25 mg and 12 doses of ambrisentan 10 mg; therefore, all were included in the safety, pharmacokinetic and pharmacodynamic assessments.</p><div id="__sec15" class="sec"><h3>Warfarin pharmacokinetics</h3><p id="__p26" class="p p-first">There were no clinically relevant effects of multiple doses of ambrisentan on the concentration–time profiles of R-and S-warfarin (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/figure/fig02/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="fig02" rid-ob="ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure 2</span></a>). Both R-and S-warfarin were detectable at the first postdose sampling time (0.5 h) and reached peak concentrations at approximately 1 h postdose. The concentration–time profiles of both warfarin enantiomers were virtually superimposable in the presence (day 13) or absence (day 1) of ambrisentan. Following multiple doses of ambrisentan, the observed mean AUC<sub>0–last</sub> values for R-and S-warfarin increased by 4.7% (GMR 104.7; 90% CI 101.7, 107.7) and 1.6% (101.6; 90% CI 98.4, 105.0), respectively, and mean <em>C</em><sub>max</sub> values decreased for both enantiomers by 8.4% (91.6; 90% CI 86.2, 97.4) and 10.1% (93.0; 90% CI 90.8, 95.3), respectively (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/table/tbl1/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl1" rid-ob="ob-tbl1" co-legend-rid=""><span>Table 1</span></a>). The 90% CIs of the GMRs for R-and S-warfarin <em>C</em><sub>max</sub> were within the predefined 80–125% no effect boundaries. Furthermore, median <em>t</em><sub>max</sub> values for both enantiomers were comparable in the presence or absence of ambrisentan.</p><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="tbl1"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/table/tbl1/" target="table" rid-ob="ob-tbl1" rid-figpopup="tbl1" class="table img_link icnblk_img figpopup"><img alt="Table 1" title="Table 1" class="small-thumb" src="./PMC2686069_files/saved_resource" src-large="/pmc/articles/PMC2686069/table/tbl1/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/table/tbl1/" target="table" rid-figpopup="tbl1" rid-ob="ob-tbl1">Table 1</a></div><!--caption a4--><div><span>Effect of ambrisentan on R-and S-warfarin pharmacokinetics</span></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="fig02" co-legend-rid="lgnd_fig02"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/figure/fig02/" target="figure" rid-figpopup="fig02" rid-ob="ob-fig02"><img src="./PMC2686069_files/bcp0067-0527-f2.gif" class="small-thumb" alt="Figure 2" title="Figure 2" src-large="/pmc/articles/PMC2686069/bin/bcp0067-0527-f2.jpg"></a><div class="icnblk_cntnt" id="lgnd_fig02"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/figure/fig02/" target="figure" rid-figpopup="fig02" rid-ob="ob-fig02">Figure 2</a></div><!--caption a4--><div><span>Mean plasma concentration <em>vs</em>. time profiles of R-warfarin (a) and S-warfarin (b) following a single oral dose of racemic warfarin 25 mg alone (□) and in the presence of multiple doses of ambrisentan (○) in 22 healthy subjects. Data are</span> <strong>...</strong></div></div></div></div><div id="__sec16" class="sec"><h3>Warfarin pharmacodynamics</h3><p id="__p31" class="p p-first">Administration of warfarin in the presence of multiple doses of ambrisentan (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/figure/fig03/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="fig03" rid-ob="ob-fig03" co-legend-rid="lgnd_fig03"><span>Figure 3</span></a>) resulted in a 14.7% decrease in INR<sub>max</sub> (85.3; 95% CI 82.4, 88.2) and a 7.0% decrease in INR<sub>AUC(0–last)</sub> (93.0; 95% CI 90.8, 95.3). The 95% CIs of the GMRs for these parameters were within the predefined 80–125% no effect boundaries (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/table/tbl2/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl2" rid-ob="ob-tbl2" co-legend-rid=""><span>Table 2</span></a>). No effect of ambrisentan on median <em>t</em><sub>max</sub> of INR was observed.</p><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="tbl2"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/table/tbl2/" target="table" rid-ob="ob-tbl2" rid-figpopup="tbl2" class="table img_link icnblk_img figpopup"><img alt="Table 2" title="Table 2" class="small-thumb" src="./PMC2686069_files/saved_resource(1)" src-large="/pmc/articles/PMC2686069/table/tbl2/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/table/tbl2/" target="table" rid-figpopup="tbl2" rid-ob="ob-tbl2">Table 2</a></div><!--caption a4--><div><span>Effect of ambrisentan on warfarin pharmacodynamics</span></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="fig03" co-legend-rid="lgnd_fig03"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/figure/fig03/" target="figure" rid-figpopup="fig03" rid-ob="ob-fig03"><img src="./PMC2686069_files/bcp0067-0527-f3.gif" class="small-thumb" alt="Figure 3" title="Figure 3" src-large="/pmc/articles/PMC2686069/bin/bcp0067-0527-f3.jpg"></a><div class="icnblk_cntnt" id="lgnd_fig03"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/figure/fig03/" target="figure" rid-figpopup="fig03" rid-ob="ob-fig03">Figure 3</a></div><!--caption a4--><div><span>Mean effect <em>vs</em>. time profile of International Normalized Ratio following a single oral dose of 25 mg racemic warfarin alone (□) and in the presence of multiple doses of ambrisentan (○) in 22 healthy subjects. Data are means ± standard</span> <strong>...</strong></div></div></div></div><div id="__sec17" class="sec"><h3>Ambrisentan pharmacokinetics</h3><p id="__p36" class="p p-first">Racemic warfarin had little effect on the steady-state plasma concentration–time profile of ambrisentan (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/figure/fig04/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="fig04" rid-ob="ob-fig04" co-legend-rid="lgnd_fig04"><span>Figure 4</span></a>). In the presence of warfarin, steady-state ambrisentan <em>C</em><sub>max</sub> and <em>C</em><sub>min</sub> decreased by 2.0% (98.0; 90% CI 87.6, 109.5) and 9.3% (90.7; 90% CI 85.5, 96.2), respectively (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/table/tbl3/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl3" rid-ob="ob-tbl3" co-legend-rid=""><span>Table 3</span></a>), and steady-state AUC<sub>0–τ</sub> (where τ is the length of the 24-h dosing interval) decreased by 12.2% (87.8; 90% CI 83.9, 91.8). The 90% CIs for all ambrisentan pharmacokinetic parameters were within the predefined no effect boundaries. Median <em>t</em><sub>max</sub> was comparable between day 12 and day 13.</p><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="tbl3"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/table/tbl3/" target="table" rid-ob="ob-tbl3" rid-figpopup="tbl3" class="table img_link icnblk_img figpopup"><img alt="Table 3" title="Table 3" class="small-thumb" src="./PMC2686069_files/saved_resource(2)" src-large="/pmc/articles/PMC2686069/table/tbl3/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/table/tbl3/" target="table" rid-figpopup="tbl3" rid-ob="ob-tbl3">Table 3</a></div><!--caption a4--><div><span>Effects of racemic warfarin on ambrisentan steady-state pharmacokinetics</span></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="fig04" co-legend-rid="lgnd_fig04"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/figure/fig04/" target="figure" rid-figpopup="fig04" rid-ob="ob-fig04"><img src="./PMC2686069_files/bcp0067-0527-f4.gif" class="small-thumb" alt="Figure 4" title="Figure 4" src-large="/pmc/articles/PMC2686069/bin/bcp0067-0527-f4.jpg"></a><div class="icnblk_cntnt" id="lgnd_fig04"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/figure/fig04/" target="figure" rid-figpopup="fig04" rid-ob="ob-fig04">Figure 4</a></div><!--caption a4--><div><span>Mean plasma concentration–time profiles of ambrisentan following multiple doses of ambrisentan alone (□) and in the presence of a single dose of warfarin (○) in 22 healthy subjects. Data are means ± standard deviation</span></div></div></div></div><div id="__sec18" class="sec sec-last"><h3>Safety and tolerability</h3><p id="__p41" class="p p-first-last">Thirteen participants (59.1%) experienced an AE during the study. The most common AEs were headache, reported in seven (31.8%) subjects, and dry skin and chapped lips, reported in three (13.6%) subjects each. There were no serious AEs, and no subjects discontinued the study due to an AE. All reported AEs were mild in severity, and only one AE of thirst was considered by the investigator to be probably related to study drug.</p></div></div><div id="__sec19" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-15"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-16">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec19title">Discussion</h2><p id="__p42" class="p p-first">In this study, multiple doses of ambrisentan 10 mg once daily resulted in slight to modest changes in R-and S-warfarin pharmacokinetic (AUC<sub>0–last</sub>,<em>C</em><sub>max</sub>) and pharmacodynamic (INR) parameters. These changes were all within the predefined equivalence criteria of 80–125%, suggesting that ambrisentan did not have a clinically relevant effect on warfarin metabolism or the resulting therapeutic effects of warfarin. Nonetheless, warfarin is a drug with a narrow therapeutic index, so that even slight changes must be considered in the context of clinical relevance.</p><p id="__p43">Drug interactions with warfarin have been previously demonstrated for the ERAs bosentan and sitaxsentan [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b9" rid="b9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_171511337" role="button" aria-expanded="false" aria-haspopup="true">9</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b14" rid="b14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_171511347" role="button" aria-expanded="false" aria-haspopup="true">14</a>–<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b16" rid="b16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_320580659" role="button" aria-expanded="false" aria-haspopup="true">16</a>]. These interactions have been attributed to alterations in the activity of CYP2C9 and CYP3A4 for bosentan and CYP2C9 for sitaxsentan, and these two enzymes are also primarily responsible for metabolism of warfarin. Bosentan, which is primarily metabolized by CYP2C9 and CYP3A4, also induces the metabolic activity of these enzymes. As a result, co-administration of bosentan with racemic warfarin in healthy subjects decreased the systemic exposure (AUC) to the R-and S-enantiomers by 38 and 29%, and these pharmacokinetic effects were associated with corresponding decreases in INR<sub>max</sub> and INR<sub>AUC(0–last)</sub> of 23 and 38% [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b14" rid="b14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_171511349" role="button" aria-expanded="false" aria-haspopup="true">14</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b15" rid="b15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_171511336" role="button" aria-expanded="false" aria-haspopup="true">15</a>]. However, clinical experience with concomitant administration of bosentan and warfarin in patients with PAH does not appear to result in any clinically relevant changes in INR or warfarin dose [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b17" rid="b17" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">17</a>]. Sitaxsentan also has an interaction with warfarin due to sitaxsentan-mediated inhibition of CYP2C9 that increases the pharmacokinetic exposure of warfarin, prolonging its effects on coagulation [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b16" rid="b16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_320580657" role="button" aria-expanded="false" aria-haspopup="true">16</a>]. The increase in INR observed with sitaxsentan co-administration requires substantial reduction in the daily dose of warfarin. For example, an 80% reduction in warfarin dose was required during the clinical studies of sitaxsentan to prevent excessive anticoagulation and the potential for serious bleeding episodes [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b16" rid="b16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_320580660" role="button" aria-expanded="false" aria-haspopup="true">16</a>].</p><p id="__p44">Ambrisentan is primarily metabolized via hepatic glucuronidation [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b10" rid="b10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_171511341" role="button" aria-expanded="false" aria-haspopup="true">10</a>–<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b12" rid="b12" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">12</a>] and does not undergo significant phase I metabolism by CYP pathways. In addition,<em>in vitro</em> studies suggest that ambrisentan does not alter the expression or activity of CYP enzymes, thus minimizing the risk for drug–drug interactions with other agents metabolized by CYP family members. In this study, ambrisentan decreased INR<sub>max</sub> and INR<sub>AUC(0–last)</sub> by 14.7 and 7.0%, respectively, with a nominal increase in AUC<sub>0–last</sub> for R-and S-warfarin of 4.7 and 1.6%, respectively. The mechanism of these minor interactions remains unknown, but is unlikely to be due to CYP inhibition or induction. Compared with bosentan, the smaller effects observed in this study are unlikely to result in any clinically relevant effects on warfarin dose or prothrombin time. The lack of a drug interaction between ambrisentan and warfarin has been corroborated in ambrisentan clinical studies that permitted the use of warfarin or warfarin-like anticoagulants as concomitant medications [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b10" rid="b10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_171511355" role="button" aria-expanded="false" aria-haspopup="true">10</a>].</p><p id="__p45" class="p p-last">In this study, both ambrisentan and warfarin were administered at clinically effective doses, and no significant changes in the pharmacokinetics or pharmacodynamics of warfarin were observed with co-administration. However, because of the small sample size, short dosing duration and the use of healthy subjects rather than patients with PAH, limited inference can be drawn from this study alone regarding the safety profile of chronic co-administration of ambrisentan and warfarin. Of note, clinical studies in patients with PAH, such as those mentioned above, have demonstrated that chronic co-administration of ambrisentan and warfarin does not appear to be associated with any specific safety concerns or need for dose adjustment of either drug [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b10" rid="b10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_171511339" role="button" aria-expanded="false" aria-haspopup="true">10</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b11" rid="b11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_320580658" role="button" aria-expanded="false" aria-haspopup="true">11</a>]. The results of this single-dose study in healthy volunteers are consistent with that conclusion. Nonetheless, warfarin is a drug with a narrow therapeutic window; therefore, caution should be exercised when initiating ambrisentan therapy in patients receiving warfarin.</p></div><div id="__sec20" class="tsec bk-sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-17"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-18">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec20title">Competing interests</h2><!--/article/back/sec/--><p id="__p46" class="p p-first">This study was funded by Myogen Inc. (now Gilead Sciences Inc.). G.W., A.M. and C.D. are employees of Gilead Sciences Inc. J.V. is an independent consultant to Gilead Sciences Inc.</p><p id="__p47" class="p p-last">We would like to acknowledge the following individuals for their contributions to the completion of this study: M. J. Gerber (Formerly of Gilead Sciences Inc.), H. A. Ghofrani (University Hospital Giessen and Marburg, Germany), H. Pentikis and L. Zhu (ICON Development Solutions).</p></div><div id="__ref-listid303549" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-19"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-20">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__ref-listid303549title">REFERENCES</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="b1">1. <span class="citation">Rubin LJ. Primary pulmonary hypertension. <span><span class="ref-journal">N Engl J Med. </span>1997;<span class="ref-vol">336</span>:111–7.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8988890" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b2">2. <span class="citation">Farber HW, Loscalzo J. Pulmonary arterial hypertension. <span><span class="ref-journal">N Engl J Med. </span>2004;<span class="ref-vol">351</span>:1655–65.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15483284" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b3">3. <span class="citation">Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. <span><span class="ref-journal">Ann Intern Med. </span>1994;<span class="ref-vol">121</span>:409–15.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8053614" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b4">4. <span class="citation">Humbert M, Sitbon O, Simmonneau G. Treatment of pulmonary arterial hypertension. <span><span class="ref-journal">N Engl J Med. </span>2004;<span class="ref-vol">351</span>:1425–36.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15459304" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b5">5. <span class="citation">Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. <span><span class="ref-journal">Clin Pharmacokinet. </span>2001;<span class="ref-vol">40</span>:587–603.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11523725" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b6">6. <span class="citation">Chan E, McLachlan A, O'Reilly R, Rowland M. Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic–pharmacodynamic model. <span><span class="ref-journal">Clin Pharmacol Ther. </span>1994;<span class="ref-vol">56</span>:286–94.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/7924124" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b7">7. <span class="citation">Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. <span><span class="ref-journal">Pharmacol Ther. </span>1997;<span class="ref-vol">73</span>:67–74.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9014207" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b8">8. <span class="citation">Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. <span><span class="ref-journal">N Engl J Med. </span>2002;<span class="ref-vol">346</span>:896–903.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11907289" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b9">9. <span class="citation">Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin V, Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RAF, Frumkin LR. Sitaxsentan therapy for pulmonary arterial hypertension. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2004;<span class="ref-vol">169</span>:441–7.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/14630619" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b10">10. <span class="citation">Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ. Ambrisentan therapy for pulmonary arterial hypertension. <span><span class="ref-journal">J Am Coll Cardiol. </span>2005;<span class="ref-vol">46</span>:529–35.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16053970" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b11">11. <span class="citation">Rubin LJ, Dufton C, Gerber M. Ambrisentan for pulmonary arterial hypertension. <span><span class="ref-journal">Future Cardiol. </span>2005;<span class="ref-vol">1</span>:1–8.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/19804142" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b12">12. <span class="citation">Gilead Sciences I. Letairis (ambrisentan) tablets for oral use.  United States Food and Drug Administration Drug Product Label, 6-15-2007.</span></div><div class="ref-cit-blk half_rhythm" id="b13">13. <span class="citation">Naidong W, Lee JW. Development and validation of a high-performance liquid chromatographic method for the quantitation of warfarin enantiomers in human plasma. <span><span class="ref-journal">J Pharm Biomed Anal. </span>1993;<span class="ref-vol">11</span>:785–92.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8218522" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b14">14. <span class="citation">Weber C, Banken L, Birnboeck H, Schulz R. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. <span><span class="ref-journal">J Clin Pharmacol. </span>1999;<span class="ref-vol">39</span>:847–54.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10434238" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b15">15. <span class="citation">Dingemanse J, Van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. <span><span class="ref-journal">Clin Pharmacokinet. </span>2004;<span class="ref-vol">43</span>:1089–115.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15568889" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b16">16. <span class="citation">Horn EM, Widlitz AC, Barst RJ. Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension. <span><span class="ref-journal">Expert Opin Investig Drugs. </span>2004;<span class="ref-vol">13</span>:1483–92.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15500395" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b17">17. <span class="citation">Actelion Pharmaceuticals Ltd. Tracleer (bosentan) tablets.  United States Food and Drug Administration Drug Product Label, 2006.</span></div></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2"><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#__abstractid588690title">Abstract</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#__sec7title">Introduction</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#__sec8title">Methods</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#__sec14title">Results</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#__sec19title">Discussion</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#__sec20title">Competing interests</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#__ref-listid303549title">REFERENCES</a></li></ul></div></div><!--post-content--><hr class="whole_rhythm no_bottom_margin"><div class="courtesy-note no_margin small">Articles from <span class="acknowledgment-journal-title">British Journal of Clinical Pharmacology</span> are provided here courtesy of <strong>British Pharmacological Society</strong></div></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="try-button"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/?report=reader"><img src="./PMC2686069_files/3838809" alt="PubReader format: click here to try"></a></div><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/epub/">ePub (beta)</a></li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/pdf/bcp0067-0527.pdf">PDF (672K)</a></li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#" data-citationid="PMC2686069" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2686069%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC2686069_files/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2686069%2F&amp;text=The%20pharmacokinetics%20and%20pharmacodynamics%20of%20warfarin%20in%20combination%20with%20ambrisentan%20in%20healthy%20volunteers" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC2686069_files/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2686069%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC2686069_files/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="19552747" data-aiid="2686069" data-aid="2686069" data-iid="179035" data-domainid="279" data-domain="brjclinpharm" data-accid="PMC2686069" data-md5="2c233f622a08ab97221feb30210cce26">
<div class="portlet pubmed_favoritesad">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Save items</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="pmfavad" toggles="ui-portlet_content-23" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-23" aria-hidden="false"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<input type="hidden" name="absid" id="absid" value="2686069"><div id="pubmed_favoritesad" class="empty" data-db="pmc">
<span role="menubar"><div class="ui-ncbisetswitch ltd-hover" role="menuitem" aria-expanded="false" aria-haspopup="true"><a href="http://www.ncbi.nlm.nih.gov/myncbi/collections/" class="jig-ncbisetswitch blind collink ltd-hover ui-ncbisetswitch-hasStar" id="favList" data-jigconfig="destSelector:&#39;#favUL&#39;,starExists:true,createCollectionUrl:&#39;#&#39;,manageCollectionsUrl:&#39;/myncbi/collections/&#39;"><span class="star"></span>Add to Favorites</a><a class="ui-ncbisetswitch-button ltd-hover" title="View more options" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#"><span class="ui-icon ui-icon-triangle-1-s ui-ncbisetswitch-down">View more options</span></a></div></span><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu ui-ncbisetswitch-popper"><ul id="favUL" class="ui-ncbisetswitch-options"></ul><ul class="ui-ncbisetswitch-actions"><li class="ui-ncbisetswitch-actions-create" style="display: block;"><a class="ui-ncbisetswitch-create-collection" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#">Create collection...</a></li><li class="ui-ncbisetswitch-actions-manage" style="display: block;"><a class="ui-ncbisetswitch-manage-collections" href="http://www.ncbi.nlm.nih.gov/myncbi/collections/">Manage collections...</a></li></ul></div>
</div>
<div class="colloading">loading</div>
<span id="submenu_AddToCollections"><form method="post"><input type="submit" class="button_apply" name="addtocollection" value="1"></form></span>
</div></div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" toggles="ui-portlet_content-25" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-25" aria-hidden="false">
<ul>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/20171423" ref="reftype=relart&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.</a><span class="source">[Clin Ther. 2010]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-27" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Vaz-da-Silva M, Almeida L, Falcão A, Soares E, Maia J, Nunes T, Soares-da-Silva P. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Ther. 2010 Jan; 32(1):179-92. </em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/20384387" ref="reftype=relart&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Effect of steady-state ambrisentan on the pharmacokinetics of a single dose of the oral contraceptive norethindrone (norethisterone) 1 mg/ethinylestradiol 35 microg in healthy subjects: an open-label, single-sequence, single-centre study.</a><span class="source">[Clin Drug Investig. 2010]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-29" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Spence R, Mandagere A, Walker G, Dufton C, Boinpally R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Drug Investig. 2010; 30(5):313-24. </em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/21496065" ref="reftype=relart&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.</a><span class="source">[Br J Clin Pharmacol. 2011]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-31" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Malhotra B, Alvey C, Gong J, Li X, Duczynski G, Gandelman K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Br J Clin Pharmacol. 2011 Aug; 72(2):257-62. </em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/22205719" ref="reftype=relart&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension.</a><span class="source">[J Clin Pharmacol. 2012]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-33" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Venitz J, Zack J, Gillies H, Allard M, Regnault J, Dufton C. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Clin Pharmacol. 2012 Dec; 52(12):1784-805. Epub 2011 Dec 28.</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/21299444" ref="reftype=relart&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Pharmacokinetic evaluation of ambrisentan.</a><span class="source">[Expert Opin Drug Metab Toxicol...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-35" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Buckley MS, Wicks LM, Staib RL, Kirejczyk AK, Varker AS, Gibson JJ, Feldman JP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Expert Opin Drug Metab Toxicol. 2011 Mar; 7(3):371-80. Epub 2011 Feb 8.</em>
</div>
</li>
</ul>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=19552747&amp;log%24=relatedreviews&amp;logdbfrom=pmc" ref="reftype=relart&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Reviews&amp;rendering-type=normal">See reviews...</a><a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=19552747&amp;log%24=relatedarticles&amp;logdbfrom=pmc" ref="reftype=relart&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Related%20Records&amp;rendering-type=normal">See all...</a>
</div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Cited by other articles in PMC</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PMCVCitedByPmcArticlesP" toggles="ui-portlet_content-37" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-37" aria-hidden="false">
<ul><li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412194/" ref="reftype=relart&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Clinical Safety, Pharmacokinetics, and Efficacy of Ambrisentan Therapy in Children With Pulmonary Arterial Hypertension</a><span class="source">[Pediatric pulmonology. 2012]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-39" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Takatsuki S, Rosenzweig EB, Zuckerman W, Brady D, Calderbank M, Ivy DD. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Pediatric pulmonology. 2012 Apr 17; 48(1)27-34</em>
</div>
</li></ul>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/citedby/" ref="reftype=relart&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|CitedBy&amp;rendering-type=normal">See all...</a>
</div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Links</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PMCVCitedByPmcArticlesP" toggles="ui-portlet_content-41" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-41" aria-hidden="false"><ul>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=books&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_books_refs&amp;IdsFromResult=2686069" ref="reftype=Cited%20in%20Books&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|Books&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Cited in Books</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-43" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Cited in Books<div class="brieflinkpopdesc">PubMed Central articles cited in books</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=pccompound&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_pccompound&amp;IdsFromResult=2686069" ref="reftype=Compound&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|PubChem%20Compound&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Compound</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-45" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Compound<div class="brieflinkpopdesc">PubChem Compound links</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=medgen&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_medgen&amp;IdsFromResult=2686069" ref="reftype=MedGen&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|Unknown%20Link%20Name&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">MedGen</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-47" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">MedGen<div class="brieflinkpopdesc">Related information in MedGen</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/19552747/" ref="reftype=PubMed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|PubMed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">PubMed</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-49" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">PubMed<div class="brieflinkpopdesc">PubMed citations for these articles</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=pcsubstance&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_pcsubstance&amp;IdsFromResult=2686069" ref="reftype=Substance&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|PubChem%20Substance&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Substance</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-51" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Substance<div class="brieflinkpopdesc">PubChem Substance links</div>
</div>
</li>
</ul></div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Recent Activity</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" toggles="ui-portlet_content-53" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-53" aria-hidden="false"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class="">
<div class="action">
<a href="javascript:historyDisplayState(&#39;ClearHT&#39;)">Clear</a><a href="javascript:historyDisplayState(&#39;HTOff&#39;)" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState(&#39;HTOn&#39;)" class="HTOff">Turn On</a>
</div>
<ul id="activity">
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c27bc04fcfad59176b5fc">The pharmacokinetics and pharmacodynamics of warfarin in combination with ambris...</a><div class="ralinkpop offscreen_noflow">The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers<div class="brieflinkpopdesc">British Journal of Clinical Pharmacology. 2009 May; 67(5)527</div>
</div>
<div class="tertiary"></div>
</li>
<li class="ra_qry two_line">
<a class="htb" ref="log$=activity&amp;linkpos=2" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c27b9f2911de5257d8dc4">PMC2686069 <span class="number">(1)</span></a><div class="tertiary">PMC</div>
</li>
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=3" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c277b04fcfad59176aad9">Assessment of a pharmacokinetic and pharmacodynamic interaction between simvasta...</a><div class="ralinkpop offscreen_noflow">Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects<div class="brieflinkpopdesc">British Journal of Clinical Pharmacology. 2009 May; 67(5)520</div>
</div>
<div class="tertiary"></div>
</li>
<li class="ra_qry two_line">
<a class="htb" ref="log$=activity&amp;linkpos=4" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c2777f0c03b798175749b">PMC2686068 <span class="number">(1)</span></a><div class="tertiary">PMC</div>
</li>
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=5" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c2766f0c03b7981757178">Tamoxifen's protection against breast cancer recurrence is not reduced by concur...</a><div class="ralinkpop offscreen_noflow">Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram<div class="brieflinkpopdesc">British Journal of Cancer. 2008 Aug 12; 99(4)616</div>
</div>
<div class="tertiary"></div>
</li>
</ul>
<p class="HTOn">Your browsing activity is empty.</p>
<p class="HTOff">Activity recording is turned off.</p>
<p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState(&#39;HTOn&#39;)">Turn recording back on</a></p>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/myncbi/recentactivity">See more...</a>
</div></div></div>
</div>
<div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p11" name="crb--__p11" rid="__p11" style="position: absolute; visibility: visible; width: 370px; top: 1658px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-55"><ul>
<li class="two_line" reference_id="b1">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/8988890/" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Primary pulmonary hypertension.</a><span class="one_line_source">[N Engl J Med.  1997]</span><div class="alt-note">
<div class="authors">Rubin LJ</div>
<div class="citation">N Engl J Med. 1997 Jan 9; 336(2):111-7.</div>
</div>
</li>
<li class="two_line" reference_id="b2" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15483284/" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Pulmonary arterial hypertension.</a><span class="one_line_source">[N Engl J Med.  2004]</span><div class="alt-note">
<div class="authors">Farber HW, Loscalzo J</div>
<div class="citation">N Engl J Med. 2004 Oct 14; 351(16):1655-65.</div>
</div>
</li>
<li class="two_line" reference_id="b3" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/8053614/" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin.</a><span class="one_line_source">[Ann Intern Med.  1994]</span><div class="alt-note">
<div class="authors">Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS</div>
<div class="citation">Ann Intern Med. 1994 Sep 15; 121(6):409-15.</div>
</div>
</li>
</ul><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/" class="seemore">See more ...</a></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p12" name="crb--__p12" rid="__p12" style="position: absolute; visibility: visible; width: 370px; top: 1753px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-56"><ul>
<li class="two_line" reference_id="b2">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15483284/" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Pulmonary arterial hypertension.</a><span class="one_line_source">[N Engl J Med.  2004]</span><div class="alt-note">
<div class="authors">Farber HW, Loscalzo J</div>
<div class="citation">N Engl J Med. 2004 Oct 14; 351(16):1655-65.</div>
</div>
</li>
<li class="two_line" reference_id="b4">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15459304/" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Treatment of pulmonary arterial hypertension.</a><span class="one_line_source">[N Engl J Med.  2004]</span><div class="alt-note">
<div class="authors">Humbert M, Sitbon O, Simonneau G</div>
<div class="citation">N Engl J Med. 2004 Sep 30; 351(14):1425-36.</div>
</div>
</li>
<li class="two_line" reference_id="b5">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/11523725/" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Pharmacogenetics of warfarin elimination and its clinical implications.</a><span class="one_line_source">[Clin Pharmacokinet.  2001]</span><div class="alt-note">
<div class="authors">Takahashi H, Echizen H</div>
<div class="citation">Clin Pharmacokinet. 2001; 40(8):587-603.</div>
</div>
</li>
<li class="two_line" reference_id="b6">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/7924124/" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model.</a><span class="one_line_source">[Clin Pharmacol Ther.  1994]</span><div class="alt-note">
<div class="authors">Chan E, McLachlan A, O'Reilly R, Rowland M</div>
<div class="citation">Clin Pharmacol Ther. 1994 Sep; 56(3):286-94.</div>
</div>
</li>
<li class="two_line" reference_id="b7">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9014207/" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Human P450 metabolism of warfarin.</a><span class="one_line_source">[Pharmacol Ther.  1997]</span><div class="alt-note">
<div class="authors">Kaminsky LS, Zhang ZY</div>
<div class="citation">Pharmacol Ther. 1997; 73(1):67-74.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p13" name="crb--__p13" rid="__p13" style="position: absolute; visibility: visible; width: 370px; top: 1995px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-57"><ul>
<li class="two_line" reference_id="b4">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15459304/" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Treatment of pulmonary arterial hypertension.</a><span class="one_line_source">[N Engl J Med.  2004]</span><div class="alt-note">
<div class="authors">Humbert M, Sitbon O, Simonneau G</div>
<div class="citation">N Engl J Med. 2004 Sep 30; 351(14):1425-36.</div>
</div>
</li>
<li class="two_line" reference_id="b8">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/11907289/" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Bosentan therapy for pulmonary arterial hypertension.</a><span class="one_line_source">[N Engl J Med.  2002]</span><div class="alt-note">
<div class="authors">Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G</div>
<div class="citation">N Engl J Med. 2002 Mar 21; 346(12):896-903.</div>
</div>
</li>
<li class="two_line" reference_id="b9">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/14630619/" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Sitaxsentan therapy for pulmonary arterial hypertension.</a><span class="one_line_source">[Am J Respir Crit Care Med.  2004]</span><div class="alt-note">
<div class="authors">Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin V, Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RA, Frumkin LR, STRIDE-1 Study Group</div>
<div class="citation">Am J Respir Crit Care Med. 2004 Feb 15; 169(4):441-7.</div>
</div>
</li>
<li class="two_line" reference_id="b10">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/16053970/" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Ambrisentan therapy for pulmonary arterial hypertension.</a><span class="one_line_source">[J Am Coll Cardiol.  2005]</span><div class="alt-note">
<div class="authors">Galié N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ</div>
<div class="citation">J Am Coll Cardiol. 2005 Aug 2; 46(3):529-35.</div>
</div>
</li>
<li class="two_line" reference_id="b11">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/19804142/" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Ambrisentan for pulmonary arterial hypertension.</a><span class="one_line_source">[Future Cardiol.  2005]</span><div class="alt-note">
<div class="authors">Rubin LJ, Dufton C, Gerber MJ</div>
<div class="citation">Future Cardiol. 2005 Jul; 1(4):425-32.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p18" name="crb--__p18" rid="__p18" style="position: absolute; visibility: visible; width: 370px; top: 3093px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-58"><ul><li class="two_line" reference_id="b13">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/8218522/" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Development and validation of a high-performance liquid chromatographic method for the quantitation of warfarin enantiomers in human plasma.</a><span class="one_line_source">[J Pharm Biomed Anal.  1993]</span><div class="alt-note">
<div class="authors">Naidong W, Lee JW</div>
<div class="citation">J Pharm Biomed Anal. 1993 Sep; 11(9):785-92.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p43" name="crb--__p43" rid="__p43" style="position: absolute; visibility: visible; width: 370px; top: 6173px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-59"><ul>
<li class="two_line" reference_id="b9">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/14630619/" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Sitaxsentan therapy for pulmonary arterial hypertension.</a><span class="one_line_source">[Am J Respir Crit Care Med.  2004]</span><div class="alt-note">
<div class="authors">Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin V, Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RA, Frumkin LR, STRIDE-1 Study Group</div>
<div class="citation">Am J Respir Crit Care Med. 2004 Feb 15; 169(4):441-7.</div>
</div>
</li>
<li class="two_line" reference_id="b14">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/10434238/" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin.</a><span class="one_line_source">[J Clin Pharmacol.  1999]</span><div class="alt-note">
<div class="authors">Weber C, Banken L, Birnboeck H, Schulz R</div>
<div class="citation">J Clin Pharmacol. 1999 Aug; 39(8):847-54.</div>
</div>
</li>
<li class="two_line" reference_id="b16">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15500395/" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.</a><span class="one_line_source">[Expert Opin Investig Drugs.  2004]</span><div class="alt-note">
<div class="authors">Horn EM, Widlitz AC, Barst RJ</div>
<div class="citation">Expert Opin Investig Drugs. 2004 Nov; 13(11):1483-92.</div>
</div>
</li>
<li class="two_line" reference_id="b15">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15568889/" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.</a><span class="one_line_source">[Clin Pharmacokinet.  2004]</span><div class="alt-note">
<div class="authors">Dingemanse J, van Giersbergen PL</div>
<div class="citation">Clin Pharmacokinet. 2004; 43(15):1089-115.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p44" name="crb--__p44" rid="__p44" style="position: absolute; visibility: visible; width: 370px; top: 6503px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-60"><ul><li class="two_line" reference_id="b10">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/16053970/" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Ambrisentan therapy for pulmonary arterial hypertension.</a><span class="one_line_source">[J Am Coll Cardiol.  2005]</span><div class="alt-note">
<div class="authors">Galié N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ</div>
<div class="citation">J Am Coll Cardiol. 2005 Aug 2; 46(3):529-35.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p45" name="crb--__p45" rid="__p45" style="position: absolute; visibility: visible; width: 370px; top: 6728px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-61"><ul>
<li class="two_line" reference_id="b10">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/16053970/" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Ambrisentan therapy for pulmonary arterial hypertension.</a><span class="one_line_source">[J Am Coll Cardiol.  2005]</span><div class="alt-note">
<div class="authors">Galié N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ</div>
<div class="citation">J Am Coll Cardiol. 2005 Aug 2; 46(3):529-35.</div>
</div>
</li>
<li class="two_line" reference_id="b11">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/19804142/" ref="reftype=pubmed&amp;article-id=2686069&amp;issue-id=179035&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Ambrisentan for pulmonary arterial hypertension.</a><span class="one_line_source">[Future Cardiol.  2005]</span><div class="alt-note">
<div class="authors">Rubin LJ, Dufton C, Gerber MJ</div>
<div class="citation">Future Cardiol. 2005 Jul; 1(4):425-32.</div>
</div>
</li>
</ul></div>
</div>
</div>   
    </div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="./PMC2686069_files/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"><div id="body-link-popper-b1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Primary pulmonary hypertension.<div class="authors">Rubin LJ</div><div class="citation">N Engl J Med. 1997 Jan 9; 336(2):111-7.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8988890/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b1">Ref list</a>]</p></div><div id="body-link-popper-b2" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Pulmonary arterial hypertension.<div class="authors">Farber HW, Loscalzo J</div><div class="citation">N Engl J Med. 2004 Oct 14; 351(16):1655-65.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15483284/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b2">Ref list</a>]</p></div><div id="body-link-popper-b3" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin.<div class="authors">Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS</div><div class="citation">Ann Intern Med. 1994 Sep 15; 121(6):409-15.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8053614/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b3">Ref list</a>]</p></div><div id="body-link-popper-b4" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Treatment of pulmonary arterial hypertension.<div class="authors">Humbert M, Sitbon O, Simonneau G</div><div class="citation">N Engl J Med. 2004 Sep 30; 351(14):1425-36.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15459304/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b4">Ref list</a>]</p></div><div id="body-link-popper-b5" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Pharmacogenetics of warfarin elimination and its clinical implications.<div class="authors">Takahashi H, Echizen H</div><div class="citation">Clin Pharmacokinet. 2001; 40(8):587-603.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11523725/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b5">Ref list</a>]</p></div><div id="body-link-popper-b6" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model.<div class="authors">Chan E, McLachlan A, O'Reilly R, Rowland M</div><div class="citation">Clin Pharmacol Ther. 1994 Sep; 56(3):286-94.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/7924124/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b6">Ref list</a>]</p></div><div id="body-link-popper-b7" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Human P450 metabolism of warfarin.<div class="authors">Kaminsky LS, Zhang ZY</div><div class="citation">Pharmacol Ther. 1997; 73(1):67-74.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9014207/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b7">Ref list</a>]</p></div><div id="body-link-popper-b8" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Bosentan therapy for pulmonary arterial hypertension.<div class="authors">Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G</div><div class="citation">N Engl J Med. 2002 Mar 21; 346(12):896-903.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11907289/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b8">Ref list</a>]</p></div><div id="body-link-popper-b9" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Sitaxsentan therapy for pulmonary arterial hypertension.<div class="authors">Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin V, Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RA, Frumkin LR, STRIDE-1 Study Group</div><div class="citation">Am J Respir Crit Care Med. 2004 Feb 15; 169(4):441-7.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/14630619/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b9">Ref list</a>]</p></div><div id="body-link-popper-b10" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Ambrisentan therapy for pulmonary arterial hypertension.<div class="authors">Galié N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ</div><div class="citation">J Am Coll Cardiol. 2005 Aug 2; 46(3):529-35.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16053970/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b10">Ref list</a>]</p></div><div id="body-link-popper-b12" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">12. <span class="citation">Gilead Sciences I. Letairis (ambrisentan) tablets for oral use.  United States Food and Drug Administration Drug Product Label, 6-15-2007.</span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b12">Ref list</a>]</div><div id="body-link-popper-b11" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Ambrisentan for pulmonary arterial hypertension.<div class="authors">Rubin LJ, Dufton C, Gerber MJ</div><div class="citation">Future Cardiol. 2005 Jul; 1(4):425-32.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/19804142/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b11">Ref list</a>]</p></div><div id="body-link-popper-b13" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Development and validation of a high-performance liquid chromatographic method for the quantitation of warfarin enantiomers in human plasma.<div class="authors">Naidong W, Lee JW</div><div class="citation">J Pharm Biomed Anal. 1993 Sep; 11(9):785-92.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8218522/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b13">Ref list</a>]</p></div><div id="body-link-popper-b14" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin.<div class="authors">Weber C, Banken L, Birnboeck H, Schulz R</div><div class="citation">J Clin Pharmacol. 1999 Aug; 39(8):847-54.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10434238/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b14">Ref list</a>]</p></div><div id="body-link-popper-b16" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.<div class="authors">Horn EM, Widlitz AC, Barst RJ</div><div class="citation">Expert Opin Investig Drugs. 2004 Nov; 13(11):1483-92.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15500395/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b16">Ref list</a>]</p></div><div id="body-link-popper-b15" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.<div class="authors">Dingemanse J, van Giersbergen PL</div><div class="citation">Clin Pharmacokinet. 2004; 43(15):1089-115.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15568889/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b15">Ref list</a>]</p></div><div id="body-link-popper-b17" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">17. <span class="citation">Actelion Pharmaceuticals Ltd. Tracleer (bosentan) tablets.  United States Food and Drug Administration Drug Product Label, 2006.</span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#b17">Ref list</a>]</div></div>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <div class="breadcrumbs">You are here: 
            <span id="breadcrumb_text"><a href="http://www.ncbi.nlm.nih.gov/guide/">NCBI</a> &gt; <a href="http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a> &gt; <a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central (PMC)</a></span></div>
    <a id="help-desk-link" class="help_desk jig-ncbihelpwindow" target="_blank" href="http://www.ncbi.nlm.nih.gov/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-06-23T14:17:32-04:00&amp;Host=ptpmc201">Write to the Help Desk</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="./PMC2686069_files/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="http://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="http://www.nlm.nih.gov/" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="http://www.nih.gov/" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="http://www.dhhs.gov/" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="http://www.usa.gov/" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            
            <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html">Copyright</a> | <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html#disclaimer">Disclaimer</a> |
            <a href="http://www.nlm.nih.gov/privacy.html" class="newdomain">Privacy</a> | 
            <a href="http://www.ncbi.nlm.nih.gov/guide/browsers/">Browsers</a> | <a href="http://www.nlm.nih.gov/accessibility.html">Accessibility</a> | <a href="http://www.ncbi.nlm.nih.gov/About/glance/contact_info.html">Contact</a>
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="http://www.ncbi.nlm.nih.gov/">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url"><a href="http://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
        </div>
    </div>
    <script type="text/javascript" src="./PMC2686069_files/InstrumentPageStarterJS.js"> </script>    
    <script type="text/javascript" src="./PMC2686069_files/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="http://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div><div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 63.5938px; left: 408.188px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: none;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686069/#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: none;">Turn off</a></div></div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript>&lt;img alt="statistics" src="/stat?jsdisabled=true&amp;amp;ncbi_db=pmc&amp;amp;ncbi_pdid=article&amp;amp;ncbi_acc=&amp;amp;ncbi_domain=brjclinpharm&amp;amp;ncbi_report=record&amp;amp;ncbi_type=fulltext&amp;amp;ncbi_objectid=&amp;amp;ncbi_pcid=/articles/PMC2686069/&amp;amp;ncbi_app=pmc" /&gt;</noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- F4FC7E8376854741_0014SID /projects/PMC/PMCViewer@4.35 ptpmc201 v4.1.r480124 Mon, Sep 28 2015 02:46:19 -->

<script type="text/javascript" src="./PMC2686069_files/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1" style="display: none;"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div><ul class="print-log"><li></li></ul></body></html>